PT. Ethica Industri Farmasi Inaugurates Rp 1 Trillion Production Plant For Injectable Drugs

Cikarang, 23 November 2017 – Today, the Indonesian Minister of Health Prof. Dr. Dr. Nila Djuwita F. Moeloek has inaugurated the new production plant of PT ETHICA Industri Farmasi, a joint venture between Fresenius Kabi AG and SOHO Global Health. The new plant was constructed on a 4.3 hectare greenfield site located in the Jababeka Industrial Complex, Cikarang, West Java. PT ETHICA Industri Farmasi has invested approximately Rp.1 trillion to set up the plant for the manufacturing of injectable drugs in ampoules and vials using aseptic and terminal sterilization technologies. PT ETHICA Industri Farmasi employs approximately 230 people at the new production plant.

Gerrit Steen, Fresenius Kabi Board Member and President for the Region Asia, states: “With this plant, PT ETHICA Industri Farmasi will be able to provide Indonesian patients with better access and a greater choice of injectable drugs for the therapy of critical and chronic diseases. These products will also contribute to meet the demand for such essential drugs in further Asian countries and Australia.”

Both aims are in line with the Indonesian instructions and regulations to accelerate the development of the pharmaceutical and medical devices industry in the country.[1]

The Minister of Health of The Republic of Indonesia, Prof. Dr. Dr. Nila Djuwita F. Moeloek, Sp.M (K); the Minister of Industry of The Republic of Indonesia, Ir. Airlangga Hartarto, MBA, MMT; Governor of West Java Ahmad Heryawan; Regent of Bekasi Neneng Hassanah Yasin and the Fresenius Kabi Board Member Gerrit Steen; Christoph Funke, Executive Vice President of Global Manufacturing Pharmaceuticals, Pharmaceuticals Division, Fresenius Kabi, along with the board of directors from PT ETHICA Industri Farmasi, and SOHO Global Health Indonesia attended the inauguration.(*tbc)

Indrawati Taurus, President Director of PT ETHICA Industri Farmasi, added, With support from Fresenius Kabi and SOHO Global Health, the joint venture company is strongly committed to the government’s National Health Insurance (JKN) program to provide world class and affordable healthcare therapies to Indonesian citizens.” The joint venture will support the country in getting a production hub for pharmaceutical products for the Asian market and contribute to the Indonesian injectable drugs industry development that grows by 11% annually. [2]

Already in 2016, the new production plant received Pharmaceutical Industry Business License from the Indonesian Ministry of Health and the Certificate of Good Manufacturing Practice from the National Food and Drug Monitoring Agency (BPOM). The plant has started its commercial operations in October 2017. An Innovation and Development Centre has been set up next to the plant to develop a broad range of injectable drugs with advanced formulations.

PT ETHICA Industri Farmasi currently offers about 20 products, e.g. in the therapeutic areas of gynecology, anesthesia, and critical care, on the Indonesian market. It is planned to triple this offer, among others by expanding the product portfolio, and to also export to other countries, e.g. Hong Kong, South Korea, Malaysia, Philippines, Singapore, Thailand, Taiwan, Vietnam and Australia.

[1]    Indonesian Presidential Instruction No. 6/2016 on the Acceleration of Development of the Pharmaceutical Industry and Medical Devices; Minister of Health Regulation No. 17/2017 on the Action Plan for Pharmaceutical Industry and Medical Instrument Development in Indonesia.

[2]    Minister of Health Regulation No. 17/2017 on the Action Plan for Pharmaceutical Industry and Medical Instrument Development in Indonesia.

About Fresenius Kabi

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.

Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems. In the field of biosimilars, the company develops products with a focus on oncology and autoimmune diseases.

With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs over 35,000 people worldwide. Fresenius Kabi’s international presence and infrastructure is one of its key strengths.


About PT ETHICA Industri Farmasi

PT SOHO Global Health’s subsidiary PT ETHICA Industri Farmasi was established as a pharmaceutical product manufacturer on 30 November 1946, at Jl. Gunung Sahari XII No. 11, Central Jakarta. It was the first pharmaceutical company to produce products in injectable form in Indonesia in 1950, and served as a role model for other pharmaceutical companies in Indonesia.

In August 1996, ETHICA relocated to a bigger premise with an area of 8,000 sqm in Kawasan Industri Pulogadung. A new production system was established in order to meet government requirements and obtain CPOB certification. In mid 1997, a Marketing team was set up to market and promote oral and injectable drugs. Since then, the company has experienced strong growth driven by committed professional employees. In 2013, Fresenius Kabi entered into a joint venture with PT SOHO Global Health, purchasing the majority of the shares to further expand PT ETHICA Industri Farmasi’s business and product portfolios.


About PT Ethica Industri Farmasi’s Production Plant

Data Details
Business Entity PT Ethica Industri Farmasi (Joint Venture with Fresenius Kabi)
Location Jl. Science Timur 2, Kawasan Industri Jababeka V,

Kav. B1B1, Cikarang Pusat, Bekasi, Jawa Barat

Total Investment IDR 1 Trillion
Total Area 4,3 ha (43,000 m² )
Total employees in the plant Approximately 230 employees
Construction Completed in 2016